Literature DB >> 2401393

Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine.

N Havu1, H Mattsson, L Ekman, E Carlsson.   

Abstract

Long-term administration of some long-acting inhibitors of gastric acid secretion has been associated with the development of gastric enterochromaffin-like (ECL)-cell carcinoids in the rat. It has been argued that short-acting, surmountable histamine H2-receptor blockers such as ranitidine do not cause carcinoids. In this study, female rats (n = 100) were treated for 2 years with the histamine H2-receptor blocker ranitidine, 2 g/kg/day in the diet. Specimens from the stomachs of all rats, including 50 controls, were stained for argyrophil cells. Plasma gastrin and ranitidine levels were measured in separate groups of rats at different times during the study. The mean plasma level of ranitidine was 37.5 mumol/l, measured at midnight when the maximal level after food intake was expected. The resulting acid inhibition was associated with an approximately 3-fold increase in plasma gastrin which persisted throughout the whole period of the study. The ranitidine treatment resulted in a pronounced hyperplasia of gastric ECL cells. In 19 rats carcinoids were found, 4 of which were micro-invasive. No carcinoids were found in the control animals. The results provide further support for the gastrin mechanism, i.e. that the development of ECL-cell carcinoids in the rat gastric mucosa is a consequence of prolonged hypergastrinaemia and is not a unique effect of any individual acid-inhibiting drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2401393     DOI: 10.1159/000200245

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  33 in total

1.  Antisecretory therapy and genotoxicity.

Authors:  S Holt; R E Powers; C W Howden
Journal:  Dig Dis Sci       Date:  1991-05       Impact factor: 3.199

2.  U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group.

Authors:  J E Valenzuela; R G Berlin; W J Snape; T L Johnson; B I Hirschowitz; J Colon-Pagan; R S Morse; J Petrozza; G M Van Deventer; A Cagliola
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

3.  Omeprazole: gastrin and gastric data (August 1991)

Authors:  R G Berlin
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

Review 4.  Antiulcer drugs and gastric cancer.

Authors:  Helge L Waldum; Bjørn Gustafsson; Reidar Fossmark; Gunnar Qvigstad
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 5.  Acid suppression and gastric mucosal cell biology.

Authors:  G Delle Fave; H Helander; S Holt; I M Modlin; R Powers; E Solcia; A Soll; Y Tielemans; N A Wright
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

Review 6.  Chemical carcinogenesis of the gastrointestinal tract in rodents: an overview with emphasis on NTP carcinogenesis bioassays.

Authors:  Sundeep A Chandra; Michael W Nolan; David E Malarkey
Journal:  Toxicol Pathol       Date:  2009-12-17       Impact factor: 1.902

7.  Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome.

Authors:  T Lehy; G Cadiot; M Mignon; P Ruszniewski; S Bonfils
Journal:  Gut       Date:  1992-09       Impact factor: 23.059

Review 8.  Animal models to study the role of long-term hypergastrinemia in gastric carcinogenesis.

Authors:  Reidar Fossmark; Gunnar Qvigstad; Tom Chr Martinsen; Øyvind Hauso; Helge L Waldum
Journal:  J Biomed Biotechnol       Date:  2010-11-24

Review 9.  Gastric cancer: animal studies on the risk of hypoacidity and hypergastrinemia.

Authors:  Reidar Fossmark; Gunnar Qvigstad; Helge-L Waldum
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  Gastric argyrophil (enterochromaffin-like), gastrin, and somatostatin cells after proximal selective vagotomy in man.

Authors:  H Koop; M Frank; S Kuly; R Nold; R Eissele; G Rager; J Rüschoff; M Rothmund; R Arnold
Journal:  Dig Dis Sci       Date:  1993-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.